From Venom to Victory: The NPS Pharma Turnaround Story

When Dr. Francois Nader took over as CEO of NPS Pharmaceuticals in 2008, its main drug had been denied regulatory approval and the company’s value had collapsed to $139M. This year NPS was sold to Shire Pharmaceuticals for $5.3B, the culmination of a stunning turnaround. Dr. Nader details the revival story and shares details about hard steps and strategic risks that turned a down-at-the-heels pharma company into a highly sought-after business.